First-in-human Safety and Immunogenicity Study of SCB-1019 in Healthy Adults

PHASE1RECRUITING

This phase 1 study in Australia will evaluate the safety, reactogenicity and immunogenicity of the bivalent SCB-1019 vaccine candidate with or without aluminium hydroxide in young adults (18-59 years) and older adults (60-85 years).

info
Simpliy with AI

Study details:

The study design includes an age- and dose-escalation (low/high dose) in two adult age groups (young adults \[18-59 years\] and older adults \[60-85 years\]). Study will be conducted in two parts, part 1 will enrolled young adults and part 2 will enroll older adults. A sentinel dosing approach will be used for close monitoring of safety to minimize risk to participants.

Detailed characterization of safety (including safety laboratory evaluation) and immune responses is planned. A placebo will be used as a control. The sample size for this study is not based on formal statistical hypothesis testing but is acceptable for safety and immunogenicity evaluation in a phase 1 study.

The study will be overseen by a safety monitoring committee.

info
Simplify with AI

Eligibility criteria

Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.

Inclusion criteria

  • Male and female participants 18 to 59 years of age (Part 1) and 60 to 85 years of age (Part 2) at the screening visit.
  • Individuals willing and able to comply with study requirements, including all scheduled visits, vaccination, laboratory tests, and other study procedures.
  • Individuals willing and able to give an informed consent, prior to screening.
  • Healthy participants as determined by medical history, physical examination, and clinical judgment of the investigator; participants with pre-existing stable medical conditions can be included (a stable medical condition is defined as a disease not requiring significant change in therapy or hospitalization for worsening disease during the 3 months before enrollment).
  • Female of childbearing potential willing to use a highly effective contraceptive method from 30 days before until 90 days after vaccination and have a negative pregnancy test on the day of vaccination; males able to father children and willing to use a highly effective contractive method from vaccination up to 90 days after vaccination, and agree to refrain from donating sperm during this period.
  • Exclusion criteria

  • Acute disease or fever (≥38°C) at time of vaccination. Participants with a minor illness (mild diarrhea, mild upper respiratory infection) without fever may be enrolled at the discretion of the investigator. For participants with minor illness and/or fever at the time of vaccination, Visit 1 may be rescheduled within the allowed time-window.
  • History of a severe adverse reaction associated with a vaccine or severe allergic reaction (e.g., anaphylaxis) to any component of the study vaccines.
  • Previous vaccination with an RSV vaccine at any time before vaccination (Day 1), or planned receipt during the study of a non-study RSV vaccine.
  • Receipt of any other licensed vaccines within 14 days before vaccination (Day 1) or planned receipt of any vaccine up to 28 days after study vaccination (Day 29).
  • Receipt of any other investigational product within 30 days before vaccination (Day 1) or intention to participate in another clinical study at any time during the conduct of this study.
  • Any condition that, in the opinion of the investigator, would interfere with the primary study objectives or pose additional risk to the participant.
  • Receipt of intravenous immunoglobulins and/or any blood products within 60 days before vaccination (Day 1) or planned administration during the study period.
  • Individuals with positive test result for hepatitis B surface antigen, hepatitis C virus antibody, and/or human immunodeficiency virus types 1 or 2 antibodies at screening.
  • Immunocompromised with known or suspected immunodeficiency, as determined by medical history and/or laboratory/physical examination (no laboratory testing required).
  • Receipt of any immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids, e.g. for cancer, organ transplantation or autoimmune disease, within three months prior to vaccination or planned receipt during the study. If a short-term course of systemic corticosteroids (<14 days) has been administered for treatment of an acute illness, participants should not be enrolled into the study until corticosteroid therapy has been discontinued for at least 28 days before study vaccination. Inhaled/nebulized, intraarticular, intrabursal, or topical (skin or eye) corticosteroids are permitted.
  • Treatment with rituximab or any other anti-CD20 monoclonal antibodies within nine months prior to vaccination or planned during the study period.
  • History of malignancy within one year before vaccination (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix which has been cured, or other malignancies with minimal risk of recurrence).
  • Any screening safety laboratory values (hematology, biochemistry, coagulation, and urinalysis) that meet the definition of a ≥Grade 1 abnormality (according to the toxicity grading)
  • info
    Simplify with AI

    Eligibility

    Age eligible for study : 18 and older

    Healthy volunteers accepted : Yes

    Gender eligible for study: All

    Things to know

    Study dates

    Study start: 2023-12-13

    Primary completion: 2024-10-01

    Study completion finish: 2025-05-01

    study type

    Study type

    PREVENTION

    phase

    Phase

      PHASE1

    trial

    Trial ID

    NCT06194318

    Intervention or treatment

    BIOLOGICAL: Candidate vaccine, SCB-1019

    BIOLOGICAL: placebo

    Conditions

    • Respiratory Syncytial Virus Infection
    Image related to Respiratory Syncytial Virus Infection
    • Condition: Respiratory Syncytial Virus Infection

    • BIOLOGICAL: Candidate vaccine, SCB-1019 and other drugs

    • Nedlands, Western Australia, Australia and more

    • Sponsor: Clover Biopharmaceuticals AUS Pty Ltd

    Find a site

    Closest Location:

    Linear Clinical Research

    Research sites nearby

    Select from list below to view details:

    • Linear Clinical Research

      Nedlands, Western Australia, Australia

    • Fusion Clinical Research

      Adelaide, Southern Australia, Australia

    Loading...

    Study Plan

    This section provides details of the study plan, including how the study is designed and what the study is measuring.

    How is the study designed?

    Participant Group/ArmIntervention/Treatment
    EXPERIMENTAL: group 1 (SCB-1019 90µg with Alum; young adults)
    • 4 young adults (18-59 years old) will receive low dose SCB-1019 (90µg, with Alum) at Day 1
    BIOLOGICAL: Candidate vaccine, SCB-1019
    • The SCB-1019 vaccine contains RSV F protein subunits from the two dominant circulating strains, A strain (SCB-1019A) and B strain (SCB-1019B). SCB-1019A and SCB-1019B are recombinant RSV F-Trimer proteins engineered by fusing the ectodomain of RSV F protein with Trimer-Tag™
    PLACEBO_COMPARATOR: group 2 (Placebo; young adults)
    • 2 young adults (18-59 years old) will receive Placebo at Day 1
    BIOLOGICAL: placebo
    • placebo
    EXPERIMENTAL: group 3 (SCB-1019 360µg with Alum; young adults)
    • 4 young adults (18-59 years old) will receive high dose SCB-1019 (360µg, with Alum) at Day 1
    BIOLOGICAL: Candidate vaccine, SCB-1019
    • The SCB-1019 vaccine contains RSV F protein subunits from the two dominant circulating strains, A strain (SCB-1019A) and B strain (SCB-1019B). SCB-1019A and SCB-1019B are recombinant RSV F-Trimer proteins engineered by fusing the ectodomain of RSV F protein with Trimer-Tag™
    PLACEBO_COMPARATOR: group 4 (Placebo; young adults)
    • 2 young adults (18-59 years old) will receive Placebo at Day 1
    BIOLOGICAL: placebo
    • placebo
    EXPERIMENTAL: group 5 (SCB-1019 90µg without Alum; older adults)
    • 10 older adults (60-85 years old) will receive low dose SCB-1019 (90µg, without Alum) at Day 1
    BIOLOGICAL: Candidate vaccine, SCB-1019
    • The SCB-1019 vaccine contains RSV F protein subunits from the two dominant circulating strains, A strain (SCB-1019A) and B strain (SCB-1019B). SCB-1019A and SCB-1019B are recombinant RSV F-Trimer proteins engineered by fusing the ectodomain of RSV F protein with Trimer-Tag™
    EXPERIMENTAL: group 6 (SCB-1019 90µg with Alum; older adults)
    • 10 older adults (60-85 years old) will receive low dose SCB-1019 (90µg, with Alum) at Day 1
    BIOLOGICAL: Candidate vaccine, SCB-1019
    • The SCB-1019 vaccine contains RSV F protein subunits from the two dominant circulating strains, A strain (SCB-1019A) and B strain (SCB-1019B). SCB-1019A and SCB-1019B are recombinant RSV F-Trimer proteins engineered by fusing the ectodomain of RSV F protein with Trimer-Tag™
    PLACEBO_COMPARATOR: group 7 (Placebo; older adults)
    • 4 older adults (60-85 years old) will receive Placebo at Day 1
    BIOLOGICAL: placebo
    • placebo
    EXPERIMENTAL: group 8 (SCB-1019 360µg without Alum; older adults)
    • 10 older adults (60-85 years old) will receive high dose SCB-1019 (360µg, without Alum) at Day 1
    BIOLOGICAL: Candidate vaccine, SCB-1019
    • The SCB-1019 vaccine contains RSV F protein subunits from the two dominant circulating strains, A strain (SCB-1019A) and B strain (SCB-1019B). SCB-1019A and SCB-1019B are recombinant RSV F-Trimer proteins engineered by fusing the ectodomain of RSV F protein with Trimer-Tag™
    EXPERIMENTAL: group 9 (SCB-1019 360µg with Alum; older adults)
    • 10 older adults (60-85 years old) will receive high dose SCB-1019 (360µg, with Alum) at Day 1
    BIOLOGICAL: Candidate vaccine, SCB-1019
    • The SCB-1019 vaccine contains RSV F protein subunits from the two dominant circulating strains, A strain (SCB-1019A) and B strain (SCB-1019B). SCB-1019A and SCB-1019B are recombinant RSV F-Trimer proteins engineered by fusing the ectodomain of RSV F protein with Trimer-Tag™
    PLACEBO_COMPARATOR: group 10 (Placebo; older adults)
    • 4 older adults (60-85 years old) will receive Placebo at Day 1
    BIOLOGICAL: placebo
    • placebo

    What is the study measuring?

    Primary outcome

    Primary Outcome MeasurePrimary Outcome DescriptionPrimary Outcome Time Frame
    Evaluate the reactogenicity of SCB-1019 vaccineProportion of participants with local and systemic solicited AEsWithin 7 days after vaccination
    Evaluate the unsolicited AEs of SCB-1019 vaccineProportion of participants with unsolicited AEsWithin 28 days after vaccination
    Evaluate the SAEs, AESIs, MAAEs, AEs leading to early termination from the study of SCB-1019 vaccineProportion of participants with SAEs, AESIs, MAAEs, AEs leading to early termination from the studyThroughout the study period, from enrollment to 6 months follow up
    Evaluate the safety and tolerability in hematology parameters of SCB-1019 vaccineMean change and shift from baseline in hematology parametersScreening and Day 8
    Evaluate the safety and tolerability in biochemistry parameters of SCB-1019 vaccineMean change and shift from baseline in biochemistry parametersScreening and Day 8
    Evaluate the safety and tolerability in coagulation parameters of SCB-1019 vaccineMean change and shift from baseline in coagulation parametersScreening and Day 8

    Secondary outcome

    Frequently Asked Questions

    Please note: some questions and answers are submitted by anonymous patients or using AI, and have not been verified by Clinrol

    No questions submitted. Be the first to ask a question!

    You may be eligible to participate in this trial based on your search.Apply for study
    Are you running this trial? If you're a clinic or sponsor, you can claim this study.Claim this trial

    References

    Clinical Trials Gov: First-in-human Safety and Immunogenicity Study of SCB-1019 in Healthy Adults

    Other trails to consider

    Top searched conditions